News | Brachytherapy Systems | September 13, 2019

Company will highlight ability of Cesium-131 brachytherapy to treat traditionally difficult cancers

Isoray to Spotlight Cesium-131 Advances at ASTRO Annual Meeting

September 13, 2019 — Isoray Inc. announced it will spotlight the growing cancer treatment applications of Cesium-131 brachytherapy at the 2019 American Society for Radiation Oncology (ASTRO) annual meeting, Sept. 15-18 in Chicago.

During the meeting, attendees will have the opportunity to learn about the mounting body of clinical evidence illustrating the expanding use of Cesium-131, now known as Cesium Blu, and its effectiveness in treating recurrent brain cancers including meningiomas and brain metastases.

Attendees will also get a first-hand look at the Blu Build real-time Cesium-131 internal radiation therapy delivery system. Blu Build is believed to be the first new delivery system in years designed specifically for prostate internal radiation therapy, according to the company. The delivery system enables doctors to deliver a high radiation dose to the targeted prostate cancer and limits the impact on the surrounding areas compared to other treatment options. 

Isoray representatives will be at the company’s booth to discuss recent developments with attendees regarding clinical applications where Cesium-131 has been found to be a potent, valuable option for clinicians and their patients.

For more information: www.isoray.com

Related Content

News | Radiation Therapy

October 19, 2021 — RAD Technology Medical Systems (RAD) announced that it will be exhibiting at the 2021 American ...

Time October 19, 2021
arrow
News | PET Imaging

October 19, 2021 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and ...

Time October 19, 2021
arrow
News | Ultrasound Women's Health

October 14, 2021 — In a first-in-world clinical trial, researchers at Sunnybrook Health Sciences Centre in Toronto ...

Time October 14, 2021
arrow
News | Lung Imaging

October 11, 2021 — According to ARRS’ American Journal of Roentgenology (AJR), percutaneous image-guided microwave and ...

Time October 11, 2021
arrow
News | Quality Assurance (QA)

October 11, 2021 — To maintain safety in radiation therapy (RT), every machine performance and patient delivery ...

Time October 11, 2021
arrow
News | Women's Health

October 8, 2021 — An analysis of nearly 200,000 patients who received mammograms between 2006 and 2015 across three U.S ...

Time October 08, 2021
arrow
News | Radiation Therapy

October 7, 2021 — NANOBIOTIX, a late-stage clinical biotechnology company pioneering physics-based approaches to expand ...

Time October 07, 2021
arrow
News | Radiation Therapy

October 7, 2021 — ViewRay, Inc. announced that the company has received acceptance from the FDA on their recent ...

Time October 07, 2021
arrow
News | Women's Health

October 5, 2021 — A promising radionuclide treatment may offer new therapeutic options for breast cancer patients ...

Time October 05, 2021
arrow
Feature | Radiation Therapy | By Dave Fornell

To maintain safety in radiation therapy (RT), every machine performance and patient delivery measurement must be as ...

Time October 05, 2021
arrow
Subscribe Now